Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.49 |
| ▸ | MLNR | O43193 | 12/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2326434 | 1.00 | HRH3 (0.49) | HRH3HRH4KDM1AMAOBRCOR1 | |
| SCHEMBL20420969 | 0.88 | ALDH1A1 (0.49) | KDM1AMLNRCYP3A4KMT2A | |
| SCHEMBL13724908 | 0.86 | MLNR (0.52) | MLNRCYP3A4KMT2A | |
| SCHEMBL17078597 | 0.84 | KDM4E (0.53) | KMT2A | |
| SCHEMBL17078932 | 0.84 | KDM4E (0.53) | KMT2A | |
| SCHEMBL17078496 | 0.84 | KDM4E (0.53) | KMT2A | |
| SCHEMBL1013993 | 0.81 | HDAC6 (0.50) | HRH3HRH4KDM1AMAOBRCOR1 | |
| SCHEMBL2329326 | 0.81 | HRH3 (0.49) | HRH3HRH4KDM1AMAOBRCOR1 | |
| SCHEMBL2329320 | 0.81 | HRH3 (0.49) | HRH3HRH4KDM1AMAOBRCOR1 | |
| SCHEMBL5059571 | 0.77 | MLNR (0.56) | HRH3HRH4MLNRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115867-A1 | NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
| US-20120115867-A1 | NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
| US-20120115867-A1 | NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
| EP-2197854-B1 | A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC SRL (IT) | 2011-08-10 | — | — | EP | disclosed |
| EP-2197854-B1 | A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC SRL (IT) | 2011-08-10 | — | — | EP | disclosed |
| US-20100305123-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2010-12-02 | — | — | US | disclosed |
| US-20100305123-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2010-12-02 | — | — | US | disclosed |
| US-20100305123-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2010-12-02 | — | — | US | disclosed |
| EP-2197854-A1 | A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.r.l. (IT) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009027395-A1 | A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009027395-A1 | A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115867-A1 | NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC5, HDAC1 | HRH3 27/4885HRH4 37/4885KDM1A 126/4885 |
| US-20100305123-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC5 | HRH3 31/4885HRH4 44/4885KDM1A 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.